SG11201907335UA - Aminotriazolopyridines as kinase inhibitors - Google Patents
Aminotriazolopyridines as kinase inhibitorsInfo
- Publication number
- SG11201907335UA SG11201907335UA SG11201907335UA SG11201907335UA SG11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA SG 11201907335U A SG11201907335U A SG 11201907335UA
- Authority
- SG
- Singapore
- Prior art keywords
- route
- princeton
- myers squibb
- line road
- squibb company
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- KGUHUVQIJHGHLX-UHFFFAOYSA-N 2h-triazolo[4,5-b]pyridin-5-amine Chemical class NC1=CC=C2NN=NC2=N1 KGUHUVQIJHGHLX-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 1
- 101150057615 Syn gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- RWYFURDDADFSHT-RBBHPAOJSA-N diane Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1.C1=C(Cl)C2=CC(=O)[C@@H]3CC3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RWYFURDDADFSHT-RBBHPAOJSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458144P | 2017-02-13 | 2017-02-13 | |
| PCT/US2018/017755 WO2018148626A1 (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907335UA true SG11201907335UA (en) | 2019-09-27 |
Family
ID=61283335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907335UA SG11201907335UA (en) | 2017-02-13 | 2018-02-12 | Aminotriazolopyridines as kinase inhibitors |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10913738B2 (ko) |
| EP (1) | EP3580220B1 (ko) |
| JP (1) | JP7097373B2 (ko) |
| KR (1) | KR102549952B1 (ko) |
| CN (1) | CN110520423B (ko) |
| AU (1) | AU2018217488B2 (ko) |
| BR (1) | BR112019016635A2 (ko) |
| CA (1) | CA3053484A1 (ko) |
| CY (1) | CY1124978T1 (ko) |
| DK (1) | DK3580220T3 (ko) |
| EA (1) | EA039808B1 (ko) |
| ES (1) | ES2902676T3 (ko) |
| HR (1) | HRP20212000T1 (ko) |
| HU (1) | HUE057801T2 (ko) |
| IL (1) | IL268614B (ko) |
| LT (1) | LT3580220T (ko) |
| MA (1) | MA47460A (ko) |
| MX (1) | MX2019009555A (ko) |
| PL (1) | PL3580220T3 (ko) |
| PT (1) | PT3580220T (ko) |
| RS (1) | RS62801B1 (ko) |
| SG (1) | SG11201907335UA (ko) |
| SI (1) | SI3580220T1 (ko) |
| WO (1) | WO2018148626A1 (ko) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS62801B1 (sr) * | 2017-02-13 | 2022-02-28 | Bristol Myers Squibb Co | Aminotriazolopiridini kao inhibitori kinaze |
| HRP20220297T1 (hr) * | 2017-10-30 | 2022-05-13 | Bristol-Myers Squibb Company | Aminoimidazopiridazini kao inhibitori kinaze |
| US11618753B2 (en) | 2018-01-26 | 2023-04-04 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| KR20210019119A (ko) | 2018-07-09 | 2021-02-19 | 리버 인스티튜트, 아이엔씨 | Nav1.8을 억제하기 위한 피리다진(PYRIDAZINE) 화합물 |
| SG11202102406XA (en) | 2018-09-13 | 2021-04-29 | Bristol Myers Squibb Co | Indazole carboxamides as kinase inhibitors |
| US20230026425A1 (en) * | 2019-01-25 | 2023-01-26 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| CA3131337C (en) * | 2019-03-22 | 2023-10-17 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
| TWI779487B (zh) * | 2020-02-13 | 2022-10-01 | 大陸商勁方醫藥科技(上海)有限公司 | 二氫萘啶酮類化合物，其製法與醫藥上的用途 |
| CN114262322A (zh) * | 2020-09-16 | 2022-04-01 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| AR123793A1 (es) | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
| AR126733A1 (es) | 2021-08-10 | 2023-11-08 | Abbvie Inc | Inhibidores de nicotinamida ripk1 |
| WO2023174374A1 (zh) | 2022-03-16 | 2023-09-21 | 江苏恒瑞医药股份有限公司 | 稠杂环类化合物、其制备方法及其在医药上的应用 |
| CN116574053A (zh) * | 2022-06-21 | 2023-08-11 | 中国药科大学 | Ripk1激酶靶点抑制剂及其医药用途 |
| WO2024146945A1 (en) | 2023-01-07 | 2024-07-11 | Syngenta Crop Protection Ag | Novel carboxamide and sulfonamide pesticidal compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008504294A (ja) | 2004-06-25 | 2008-02-14 | アムジエン・インコーポレーテツド | サイトカイン介在疾患および他の疾患の治療において有用な縮合トリアゾールおよびインダゾール |
| EP2001480A4 (en) * | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| BRPI0819606A2 (pt) | 2007-11-27 | 2017-05-09 | Cellzome Ltd | amino triazóis como inobidores de pi3k |
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| EP2393813B1 (en) | 2009-02-04 | 2013-07-31 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| EA201501175A1 (ru) | 2013-06-10 | 2016-10-31 | Байер Фарма Акциенгезельшафт | Новые соединения для лечения злокачественного новообразования |
| AU2015304851A1 (en) * | 2014-08-21 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as RIP1 kinase inhibitors as medicaments |
| EP3372604B1 (en) | 2015-11-05 | 2021-12-01 | Sumitomo Chemical Company, Limited | Condensed heterocyclic compound |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| CN110198942B (zh) | 2017-01-24 | 2022-04-15 | 住友化学株式会社 | 稠合杂环化合物及含有其的组合物 |
| RS62801B1 (sr) * | 2017-02-13 | 2022-02-28 | Bristol Myers Squibb Co | Aminotriazolopiridini kao inhibitori kinaze |
| HRP20220297T1 (hr) | 2017-10-30 | 2022-05-13 | Bristol-Myers Squibb Company | Aminoimidazopiridazini kao inhibitori kinaze |
| US11618753B2 (en) | 2018-01-26 | 2023-04-04 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2018
- 2018-02-12 RS RS20220021A patent/RS62801B1/sr unknown
- 2018-02-12 KR KR1020197026464A patent/KR102549952B1/ko active IP Right Grant
- 2018-02-12 CN CN201880024064.1A patent/CN110520423B/zh active Active
- 2018-02-12 HU HUE18707498A patent/HUE057801T2/hu unknown
- 2018-02-12 SG SG11201907335UA patent/SG11201907335UA/en unknown
- 2018-02-12 WO PCT/US2018/017755 patent/WO2018148626A1/en unknown
- 2018-02-12 AU AU2018217488A patent/AU2018217488B2/en active Active
- 2018-02-12 ES ES18707498T patent/ES2902676T3/es active Active
- 2018-02-12 PT PT187074984T patent/PT3580220T/pt unknown
- 2018-02-12 EP EP18707498.4A patent/EP3580220B1/en active Active
- 2018-02-12 PL PL18707498T patent/PL3580220T3/pl unknown
- 2018-02-12 LT LTEPPCT/US2018/017755T patent/LT3580220T/lt unknown
- 2018-02-12 EA EA201991915A patent/EA039808B1/ru unknown
- 2018-02-12 BR BR112019016635A patent/BR112019016635A2/pt unknown
- 2018-02-12 US US16/484,604 patent/US10913738B2/en active Active
- 2018-02-12 DK DK18707498.4T patent/DK3580220T3/da active
- 2018-02-12 MX MX2019009555A patent/MX2019009555A/es unknown
- 2018-02-12 HR HRP20212000TT patent/HRP20212000T1/hr unknown
- 2018-02-12 JP JP2019543377A patent/JP7097373B2/ja active Active
- 2018-02-12 MA MA047460A patent/MA47460A/fr unknown
- 2018-02-12 SI SI201830511T patent/SI3580220T1/sl unknown
- 2018-02-12 CA CA3053484A patent/CA3053484A1/en active Pending
-
2019
- 2019-08-09 IL IL268614A patent/IL268614B/en unknown
-
2020
- 2020-12-09 US US17/116,016 patent/US20220315580A1/en active Pending
-
2022
- 2022-01-18 CY CY20221100043T patent/CY1124978T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3580220T (lt) | 2021-12-27 |
| US20220315580A1 (en) | 2022-10-06 |
| CN110520423A (zh) | 2019-11-29 |
| US20190389859A1 (en) | 2019-12-26 |
| HRP20212000T1 (hr) | 2022-04-01 |
| EP3580220B1 (en) | 2021-11-17 |
| CY1124978T1 (el) | 2023-01-05 |
| US10913738B2 (en) | 2021-02-09 |
| MX2019009555A (es) | 2019-10-02 |
| KR102549952B1 (ko) | 2023-06-29 |
| EA201991915A1 (ru) | 2019-12-30 |
| IL268614A (en) | 2019-10-31 |
| BR112019016635A2 (pt) | 2020-04-07 |
| MA47460A (fr) | 2019-12-18 |
| PL3580220T3 (pl) | 2022-02-07 |
| PT3580220T (pt) | 2022-01-03 |
| AU2018217488B2 (en) | 2021-09-23 |
| HUE057801T2 (hu) | 2022-06-28 |
| DK3580220T3 (da) | 2022-01-10 |
| EP3580220A1 (en) | 2019-12-18 |
| EA039808B1 (ru) | 2022-03-16 |
| RS62801B1 (sr) | 2022-02-28 |
| IL268614B (en) | 2021-12-01 |
| AU2018217488A1 (en) | 2019-10-03 |
| JP2020507582A (ja) | 2020-03-12 |
| CA3053484A1 (en) | 2018-08-16 |
| JP7097373B2 (ja) | 2022-07-07 |
| SI3580220T1 (sl) | 2022-01-31 |
| WO2018148626A1 (en) | 2018-08-16 |
| ES2902676T3 (es) | 2022-03-29 |
| CN110520423B (zh) | 2022-08-23 |
| KR20190117006A (ko) | 2019-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907335UA (en) | Aminotriazolopyridines as kinase inhibitors | |
| SG11201807980QA (en) | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer | |
| SG11201811321TA (en) | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists | |
| SG11201805927YA (en) | Spiroheptane salicylamides and related compounds as inhibitors of rock | |
| SG11201811590RA (en) | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds | |
| SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201900619XA (en) | Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201909429VA (en) | 3-(((((2s,5r)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl)oxy)sulfonyl)oxy)-2,2-dimethylprop noate derivatives and related compounds as perorally administered profrugs of beta-lactamase inhibitors for treating bacterial infections | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201907216WA (en) | Adjustable flow nozzle system | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201804674UA (en) | Heteroarylhydroxypyrimidinones as agonists of the apj receptor | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| SG11201811671XA (en) | Prins reaction and intermediates useful in the synthesis of halichondrin macrolides and analogs thereof | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201810389XA (en) | New antibacterial compounds |